NO20060259L - Melanocortinreseptor 4(MC4) agonist og anvendelser derav - Google Patents

Melanocortinreseptor 4(MC4) agonist og anvendelser derav

Info

Publication number
NO20060259L
NO20060259L NO20060259A NO20060259A NO20060259L NO 20060259 L NO20060259 L NO 20060259L NO 20060259 A NO20060259 A NO 20060259A NO 20060259 A NO20060259 A NO 20060259A NO 20060259 L NO20060259 L NO 20060259L
Authority
NO
Norway
Prior art keywords
agonist
melanocortin receptor
peptide agonists
receptor
obesity
Prior art date
Application number
NO20060259A
Other languages
English (en)
Norwegian (no)
Inventor
Hansen Maxwell Hsiung
Mark Louis Heiman
David B Flora
Lianshan Zhang
Jeanne L Hertel
John Philip Mayer
David Lee Smiley
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20060259L publication Critical patent/NO20060259L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20060259A 2003-06-19 2006-01-18 Melanocortinreseptor 4(MC4) agonist og anvendelser derav NO20060259L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47974003P 2003-06-19 2003-06-19
US55734704P 2004-03-29 2004-03-29
US57067604P 2004-05-13 2004-05-13
US57073704P 2004-05-13 2004-05-13
PCT/US2004/016625 WO2005000339A2 (en) 2003-06-19 2004-06-17 Melanocortin receptor 4(mc4) agonists and their uses

Publications (1)

Publication Number Publication Date
NO20060259L true NO20060259L (no) 2006-03-14

Family

ID=33556652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060259A NO20060259L (no) 2003-06-19 2006-01-18 Melanocortinreseptor 4(MC4) agonist og anvendelser derav

Country Status (17)

Country Link
US (1) US20070105759A1 (es)
EP (1) EP1644023A2 (es)
JP (1) JP2006527773A (es)
KR (1) KR20060014444A (es)
AR (1) AR044824A1 (es)
AU (1) AU2004251616A1 (es)
BR (1) BRPI0410731A (es)
CA (1) CA2530024A1 (es)
CR (1) CR8159A (es)
EA (1) EA200600055A1 (es)
EC (1) ECSP056236A (es)
IL (1) IL171931A0 (es)
MX (1) MXPA05013951A (es)
NO (1) NO20060259L (es)
PE (1) PE20050284A1 (es)
TW (1) TW200514791A (es)
WO (1) WO2005000339A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ES2286679T3 (es) 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
ES2663916T3 (es) * 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
EP1915168A4 (en) * 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2979703B1 (en) 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
EP2238244A1 (en) 2008-01-02 2010-10-13 Danisco A/S Pseudomonas saccharophila g4-amylase variants and uses thereof
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2018003983A (es) 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR101917854B1 (ko) * 2017-08-24 2018-11-12 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
CN115010793A (zh) * 2022-06-17 2022-09-06 中国农业大学 玫瑰叶畸形病毒外壳蛋白多克隆抗体的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
GB9808229D0 (en) * 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
MXPA01005818A (es) * 1998-12-09 2003-07-21 Eleanor Rooseveltl Inst Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas.
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
HK1044954B (en) * 1999-03-29 2008-11-21 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6659982B2 (en) * 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
PT1315750E (pt) * 2000-08-30 2007-05-31 Hoffmann La Roche Péptidos cíclicos com actividade agonista para o receptor 4 de melanocortina
WO2003006604A2 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
EA200600055A1 (ru) 2006-08-25
JP2006527773A (ja) 2006-12-07
WO2005000339A2 (en) 2005-01-06
KR20060014444A (ko) 2006-02-15
WO2005000339A8 (en) 2005-04-21
WO2005000339A3 (en) 2005-02-03
IL171931A0 (en) 2006-04-10
TW200514791A (en) 2005-05-01
US20070105759A1 (en) 2007-05-10
MXPA05013951A (es) 2006-02-24
CR8159A (es) 2006-02-09
CA2530024A1 (en) 2005-01-06
ECSP056236A (es) 2006-04-19
EP1644023A2 (en) 2006-04-12
AU2004251616A1 (en) 2005-01-06
AR044824A1 (es) 2005-10-05
BRPI0410731A (pt) 2006-06-20
PE20050284A1 (es) 2005-05-20

Similar Documents

Publication Publication Date Title
TW200514791A (en) Melanocortin receptor 4(MC4) agonists and their uses
ATE342057T1 (de) Melanocortinrezeptoragonisten
WO2005030797A3 (en) Melanocortin receptor agonists
WO2008147556A3 (en) Melanocortin receptor ligands modified with hydantoin
NO20080052L (no) G-Protein kopplede reseptoragonister
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
WO2002059117A8 (en) Piperazine- and piperidine-derivatives as melanocortin receptor agonists
ECSP045094A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
BR0207658A (pt) Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
WO2008106429A3 (en) Methods and compositions for the treatment of heart failure and other disorders
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
WO2002059107A8 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
BR0107893A (pt) Agonistas e antagonistas de receptor de melanocortina
WO2007109135A3 (en) Neuromedin u receptor agonists and uses thereof
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
WO2005009950A3 (en) Piperidine derivatives as melanocortin-4 receptor agonists
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
PT1988914E (pt) Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
PT1768985E (pt) Derivados de pirimido-benzimidazole e sua utilização como agonistas ou antagonistas dos receptores das melanocortinas
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
WO2006052626A3 (en) Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders
WO2006121588A3 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application